161 related articles for article (PubMed ID: 37238613)
1. Liposomal DQ in Combination with Copper Inhibits ARID1A Mutant Ovarian Cancer Growth.
Kang X; Wang Q; Wu S; Wang C; Annaji M; Huang CH; Shen J; Chen P; Babu RJ
Biomolecules; 2023 Apr; 13(5):. PubMed ID: 37238613
[TBL] [Abstract][Full Text] [Related]
2. Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells.
Kwan SY; Cheng X; Tsang YT; Choi JS; Kwan SY; Izaguirre DI; Kwan HS; Gershenson DM; Wong KK
Oncotarget; 2016 Aug; 7(35):56933-56943. PubMed ID: 27486766
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers.
Ogiwara H; Takahashi K; Sasaki M; Kuroda T; Yoshida H; Watanabe R; Maruyama A; Makinoshima H; Chiwaki F; Sasaki H; Kato T; Okamoto A; Kohno T
Cancer Cell; 2019 Feb; 35(2):177-190.e8. PubMed ID: 30686770
[TBL] [Abstract][Full Text] [Related]
4. Near-infrared light triggered activation of pro-drug combination cancer therapy and induction of immunogenic cell death.
Kang X; Cai Y; Wang Q; Wang C; Chen W; Yang W; Suryawanshi A; Zhou G; Chen P; Li F
Int J Pharm; 2021 Sep; 607():120972. PubMed ID: 34363916
[TBL] [Abstract][Full Text] [Related]
5. EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-X
Inoue-Yamauchi A; Oda H
Biochem Biophys Res Commun; 2020 Jun; 526(3):612-617. PubMed ID: 32247610
[TBL] [Abstract][Full Text] [Related]
6. Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in
Zundell JA; Fukumoto T; Lin J; Fatkhudinov N; Nacarelli T; Kossenkov AV; Liu Q; Cassel J; Hu CA; Wu S; Zhang R
Cancer Res; 2021 Oct; 81(20):5325-5335. PubMed ID: 34548333
[TBL] [Abstract][Full Text] [Related]
7. Targeting redox vulnerability of cancer cells by prooxidative intervention of a glutathione-activated Cu(II) pro-ionophore: Hitting three birds with one stone.
Bao XZ; Dai F; Li XR; Zhou B
Free Radic Biol Med; 2018 Aug; 124():342-352. PubMed ID: 29935260
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
[TBL] [Abstract][Full Text] [Related]
9. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.
Haslehurst AM; Koti M; Dharsee M; Nuin P; Evans K; Geraci J; Childs T; Chen J; Li J; Weberpals J; Davey S; Squire J; Park PC; Feilotter H
BMC Cancer; 2012 Mar; 12():91. PubMed ID: 22429801
[TBL] [Abstract][Full Text] [Related]
10. Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival.
Amano Y; Mandai M; Yamaguchi K; Matsumura N; Kharma B; Baba T; Abiko K; Hamanishi J; Yoshioka Y; Konishi I
Oncotarget; 2015 Sep; 6(28):26002-17. PubMed ID: 26318292
[TBL] [Abstract][Full Text] [Related]
11. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
12. Cascade-amplified self-immolative polymeric prodrug for cancer therapy by disrupting redox homeostasis.
Dey A; Jeon J; Yoon B; Li Y; Park JH
J Control Release; 2023 Jun; 358():555-565. PubMed ID: 37182804
[TBL] [Abstract][Full Text] [Related]
13. Fe
Xue P; Li J; Song J; Yu J; Liu H; Jiang Y; Wang Y
Int J Pharm; 2024 Jan; 649():123657. PubMed ID: 38040398
[TBL] [Abstract][Full Text] [Related]
14. Iodinated chlorin p
Sarbadhikary P; Dube A
Chem Biol Interact; 2017 Nov; 277():137-144. PubMed ID: 28918125
[TBL] [Abstract][Full Text] [Related]
15. Reactive oxygen species-responsive nanoprodrug with quinone methides-mediated GSH depletion for improved chlorambucil breast cancers therapy.
Luo CQ; Zhou YX; Zhou TJ; Xing L; Cui PF; Sun M; Jin L; Lu N; Jiang HL
J Control Release; 2018 Mar; 274():56-68. PubMed ID: 29409835
[TBL] [Abstract][Full Text] [Related]
16. CYT-Rx20 inhibits ovarian cancer cells in vitro and in vivo through oxidative stress-induced DNA damage and cell apoptosis.
Wang YY; Chen YK; Hu SC; Hsu YL; Tsai CH; Chi TC; Huang WL; Hsieh PW; Yuan SF
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1129-1140. PubMed ID: 28500555
[TBL] [Abstract][Full Text] [Related]
17. Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries.
Zhang X; Shetty M; Clemente V; Linder S; Bazzaro M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947138
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer stem cell proliferation is strongly inhibited by diethyldithiocarbamate-copper complex loaded into hyaluronic acid decorated liposomes.
Marengo A; Forciniti S; Dando I; Dalla Pozza E; Stella B; Tsapis N; Yagoubi N; Fanelli G; Fattal E; Heeschen C; Palmieri M; Arpicco S
Biochim Biophys Acta Gen Subj; 2019 Jan; 1863(1):61-72. PubMed ID: 30267751
[TBL] [Abstract][Full Text] [Related]
19. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
Kim M; Lu F; Zhang Y
Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
[TBL] [Abstract][Full Text] [Related]
20.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
